<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004180</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067406</org_study_id>
    <secondary_id>P30CA006516</secondary_id>
    <secondary_id>DFCI-99083</secondary_id>
    <secondary_id>NCI-G99-1629</secondary_id>
    <nct_id>NCT00004180</nct_id>
  </id_info>
  <brief_title>Rosiglitazone in Treating Patients With Liposarcoma</brief_title>
  <official_title>Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who&#xD;
      have liposarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical activity of rosiglitazone in patients with liposarcoma.&#xD;
&#xD;
        -  Assess the impact of this regimen on markers of tumor proliferation and differentiation&#xD;
           status in these patients using biologic and biochemical testing and correlative imaging.&#xD;
&#xD;
        -  Determine the tolerance and safety of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified by histologic subtype (well differentiated vs&#xD;
      dedifferentiated vs myxoid/round cell vs pleomorphic).&#xD;
&#xD;
      Patients receive oral rosiglitazone twice daily. Treatment continues in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 1-3 weeks and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 56-120 patients (14-30 per stratum) will be accrued for this&#xD;
      study within 15 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of biological response</measure>
    <description>Evidence of biological response can be measured or defined by intracytoplasmic microvesicular lipid accumulation, consistent with adipocytic differentiation in liposarcoma cells. Biological response can also be measured by clinically stable disease for x&gt;3 months, as well as standard clinical trial criteria for &quot;objective clinical response.&quot; Complete response is defined by total resolution of all detectable disease lasting for at least four weeks. Partial remission is a decrease of over 50% in the sum of the products of the largest perpendicular diameters of all measurable lesions, persisting for at least four weeks, without progression of any non-measurable sites, and without appearance of any new sites of disease.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Well-differentiated liposarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>De-differentiated liposarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myxoid/ round-cell liposarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pleomorphic liposarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone maleate</intervention_name>
    <arm_group_label>De-differentiated liposarcoma</arm_group_label>
    <arm_group_label>Myxoid/ round-cell liposarcoma</arm_group_label>
    <arm_group_label>Pleomorphic liposarcoma</arm_group_label>
    <arm_group_label>Well-differentiated liposarcoma</arm_group_label>
    <other_name>Rosiglitazone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven liposarcoma that is incurable with standard multimodality&#xD;
             approaches (e.g., surgery and/or radiotherapy and/or chemotherapy)&#xD;
&#xD;
               -  Well differentiated OR&#xD;
&#xD;
               -  Dedifferentiated OR&#xD;
&#xD;
               -  Myxoid/round cell OR&#xD;
&#xD;
               -  Pleomorphic&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No clinically unstable brain metastases&#xD;
&#xD;
          -  No progression on prior troglitazone therapy for liposarcoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT less than 5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.4 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No poorly controlled atrial arrhythmias, symptomatic angina pectoris, or myocardial&#xD;
             infarction within the past 4 months&#xD;
&#xD;
          -  No symptomatic congestive heart failure, percutaneous transluminal coronary&#xD;
             angioplasty, or coronary artery bypass graft within the past 3 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
               -  Oral contraceptives are not considered effective contraception&#xD;
&#xD;
          -  No active retroviral disease&#xD;
&#xD;
          -  No condition that would preclude informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior chemotherapy allowed and recovered&#xD;
&#xD;
          -  No concurrent cytotoxic therapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior radiotherapy allowed and recovered&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy to the sole site of measurable disease&#xD;
&#xD;
          -  Concurrent localized radiotherapy to a single site of disease allowed if there are&#xD;
             other sites of measurable disease&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George D. Demetri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>January 21, 2000</study_first_submitted>
  <study_first_submitted_qc>May 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2003</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>George Demetri, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>adult liposarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

